ADAM29 Antibody

Product Specifications

Background

The ADAM (a disintegrin and metalloprotease) protein family plays a role in cell-cell and cell-matrix interface related processes, including fertilization, muscle fusion, secretion of TNFalpha (tumor necrosis factor alpha), and modulation of the neurogenic function of Notch and Delta (1-3) . ADAM29 contains one disintegrin domain, one EGF-like domain and one peptidase M12B domain (2) . It is highly expressed in testes (3) and may be involved in spermatogenesis and fertilization (4,5) .

NCBI Gene ID

11086

Swiss Prot

Q9UKF5

Accession Number

NP_055084

Host

Rabbit

Reactivity

Human

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Homeostasis, Stem Cell

Purification

ADAM29 antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1310 - Human Bladder Tissue Lysate

Concentration

1 mg/mL

Buffer

ADAM29 antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

ADAM29 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year.

Fragment

IgG

Specificity

ADAM29 antibody is human specific. ADAM29 antibody is predicted to not cross-react with other ADAM family proteins.

Symbol

ADAM29

Positive Control 2

Cat. No. 11-701 - Human Testis Tissue Slide

NCBI Official Name

ADAM metallopeptidase domain 29

NCBI Organism

Homo sapiens

Background Reference 01

Wang F, Xu R, Zhu P, et al. Preliminarily functional analysis of a cloned novel human gene ADAM29. Sci. China C. Life Sci. 2001; 44392-9.

Background Reference 02

Xu R, Cai J, Xu T, et al. Molecular cloning and mapping of a novel ADAM gene (ADAM29) to human chromosome 4. Genomics 1999; 62:537-9.

Background Reference 03

Cerretti DP, DuBose RF, Black RA, et al. Isolation of two novel metalloproteinase-disintegrin (ADAM) cDNAs that show testis-specific gene expression. Biochem. Biophys. Res. Commun. 1999; 263:810-5.

Background Reference 04

Oppezzo P, Vasconcelos Y, Settegrana C, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005; 106:650-7.